Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
B., Milligan, G
HRS-4729 is the earlier-stage triple-agonist backup within that portfolio
Italy Spain Rest of Europe Asia Pacific China Japan India South Korea South-east Asia Rest of Asia Pacific Latin America Brazil Argentina Rest of Latin America Middle East & Africa GCC Countries South Africa Rest of the Middle East and Africa Competitive Landscape The competitive landscape of the Liraglutide and Semaglutide market includes major players such as Bachem Holding AG, Novo Nordisk A/S, Eli Lilly and Company, HEC Pharma Co., Pfizer Inc., Boehringer Ingelheim International GmbH, Shenzhen JYMed Technology Co
Take the 30 seconds to clear bubbles every time
This approval makes Eli Lillys oral GLP-1 receptor agonist, to be marketed as Foundayo, the second GLP-1 drug for weight loss available in pill form, after Wegovy, which gained approval in December 2025
